Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial.

MLA

Maojin You, et al. “Enfortumab Vedotin plus Pembrolizumab as a First-Line Treatment for Advanced Urothelial Carcinoma: A Cost-Effectiveness Analysis from China Based on the EV-302 Trial.” Frontiers in Pharmacology, Oct. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.3389/fphar.2024.1412292.

APA

Maojin You, Qiaoyan Zheng, & Ying He. (2024). Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial. Frontiers in Pharmacology, 1–12. https://doi.org/10.3389/fphar.2024.1412292

Chicago

Maojin You, Qiaoyan Zheng, and Ying He. 2024. “Enfortumab Vedotin plus Pembrolizumab as a First-Line Treatment for Advanced Urothelial Carcinoma: A Cost-Effectiveness Analysis from China Based on the EV-302 Trial.” Frontiers in Pharmacology, October, 1–12. doi:10.3389/fphar.2024.1412292.